Anti-viral chimeric protein RetroMAD1™ potently block SARS-CoV-2 viral entry and propagation

Author:

Chan Lee-Chin1,Yassim Aini Syahida Mat1,Leow Thean Chor2,Sabri Suriana2,Yahaya Radin Shafierul Radin2,Bakar Awang Muhammad Sagaf Abu3

Affiliation:

1. Biovalence Sdn. Bhd.

2. Universiti Putra Malaysia

3. Jabatan Perkhidmatan Veterinar

Abstract

Abstract COVID-19 is a disease caused by the highly transmissible and pathogenic SARS-CoV-2 virus. Since its first case was documented in 2019, it has rapidly widespread and has caused millions of deaths worldwide. Many intervention strategies targeting these proteins have been developed. However, frequently mutation of SARS-CoV-2 poses a challenge to the effectiveness of current treatments. Therefore, it is critical to develop new therapeutic drugs against this disease. In this present study, in silico approach was used to study the interaction between RetroMAD1™and SARS-CoV-2 proteins including Spike proteins (S), 3-chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro). The interaction of these viral proteins and RetroMAD1™ was performed through HDOCK server and visualised using PyMOL. Docking results revealed that all the complexes of SARS-CoV-2 proteins binding with RetroMAD1™ have relatively high docking scores. The binding energy of RetroMAD1™ complexes with SARS-CoV-2 S, 3CLpro, PLpro were − 15, -12.3 and − 15.4, respectively. RetroMAD1™antiviral efficiency and cytotoxicity was also evaluated using EpiAirway™ Model. In vitro validation of viral inhibitory effect of RetroMAD1™was performed with 3CLpro Inhibition Assay. The outcome showed that RetroMAD1™ represents a potential drug candidate against SARS-CoV-2 for its promising viral inhibitory effect.

Publisher

Research Square Platform LLC

Reference65 articles.

1. Why scientists are racing to develop more COVID antivirals;Kozlov M;Nature.,2002

2. NIH, N. I. O. H. Antiviral Drugs That Are Approved, Authorized, or Under Evaluation for the Treatment of COVID-19 [Online]. Available: https://www.COVID19treatmentguidelines.nih.gov/therapies/antiviral-therapy/summary-recommendations/#:~:text=Remdesivir%20is%20the%20only%20drug,the%20treatment%20of%20COVID%2D19 (Accessed April 12, 2022).

3. The race for antiviral drugs to beat COVID - and the next pandemic;Dolgin E;Nature.,2021

4. Case studies on RetroMAD1™, an orally administered recombinant chimeric protein to treat naturally infected Feline Leukemia Virus (FeLV) cats;Huan UE;Archives of Veterinary Science and Medicine.,2019

5. Antimicrobial fusion compounds and uses thereof;Bakar AMSA;U.S. Patent No.,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3